OPEN END TURBO PUT WARRANT - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 12:03:02 13/06/2024 BST | ||
| 20.31 EUR | -1.98% |
|
| Current month | -18.20% | ||
| 1 month | -31.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 20.31 | -1.98% |
| 12/06/24 | 20.72 | +9.98% |
| 11/06/24 | 18.84 | -12.21% |
| 10/06/24 | 21.46 | -2.01% |
| 07/06/24 | 21.9 | -6.33% |
Real-time Boerse Frankfurt Warrants
Last update June 13, 2024 at 12:03 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UM2DZD |
| ISIN | DE000UM2DZD0 |
| Date issued | 07/02/2024 |
| Strike | 1,089 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 35.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.67 € |
|---|---|
| Lowest since issue | 18.21 € |
| Spread | 0.12 € |
| Spread % | 0.59% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
867.3
USD
Average target price
855.2
USD
Spread / Average Target
-1.40%
- Stock Market
- Certificates
- Certificat
